Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Aclaris Therapeutics () last issued its quarterly earnings results on Tuesday, November 8th.
Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2024 earnings at ($1.59) EPS.
Cantor Fitzgerald reiterated an “overweight” rating and issued a $38.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday, February 7th.